COR · 10-Q · 2026Q2 · Full report
GLP-1 Product Demand
Cencora, Inc. · 2026-08-05 · Importance 47 · Surprise 48 · In source text
Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased $2.3 billion, or 25.5%, in the quarter and $5.2 billion, or 19.7%, year to date. GLP-1 demand was a major contributor to U.S. Healthcare Solutions’ unit-volume growth. These products carry lower gross profit margins than the company’s broader pharmaceutical mix, creating a product-mix pressure despite strong demand.
Key facts
- Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased by $2.3 billion, or 25.5%, from the prior year quarter and by $5.2 billion, or 19.7%, from the prior year nine-month period. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +6.1% | Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased by $2.3 billion, or 25.5%, from the prior year… |
| revenue | positive | realized | +2.7% | Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased by $2.3 billion, or 25.5%, from the prior year… |